The company
Disc Medicine, Inc.
IRON · Nasdaq
IRON stood above a rising 150-day average in 20 of the last 52 weekly readings, including each of the last 1 week. It is 12.7% above that average now. Biotechnology: 18% of its 561 stocks in an uptrend (−14 points in four weeks); Health Care: 28% (−9 points in four weeks).
Statistics
- Rotation
- Just started moving
- Weeks in an uptrend
- 1 in a row
- Industry in uptrend
- 18% -14 in 4 wk
- Insider buys, 12 months
- $0
- Insider sales, 12 months
- $128.8M
- Officials’ trades on record
- 0
- Institutions holding
- 203 (+10)
In the rotation
Each square a week: lit when it closed above a rising 150-day average. 20 of 52 weeks.
Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.
Money in and out
Open-market buys above the line and sales below, in dollars.
Congress and officials
No member of Congress or official has disclosed a trade in it.
Insiders
| Who | Did | Shares | Traded |
|---|---|---|---|
| Kevin BittermanDirector | sold | 27,136at $70.11 | 11 Sep 2026filed 15 Sep 2026 |
| Kevin BittermanDirector | sold | 912at $79.96 | 4 Sep 2026filed 9 Sep 2026 |
| Kevin BittermanDirector | sold | 759at $79.96 | 4 Sep 2026filed 9 Sep 2026 |
| Kevin BittermanDirector | sold | 18at $79.96 | 4 Sep 2026filed 9 Sep 2026 |
| Kevin BittermanDirector | sold | 2,810at $79.98 | 3 Sep 2026filed 3 Sep 2026 |
| Kevin BittermanDirector | sold | 2,339at $79.98 | 3 Sep 2026filed 3 Sep 2026 |
| Kevin BittermanDirector | sold | 54at $79.98 | 3 Sep 2026filed 3 Sep 2026 |
| Kevin BittermanDirector | sold | 26,542at $80.17 | 2 Sep 2026filed 3 Sep 2026 |
| Kevin BittermanDirector | sold | 22,090at $80.17 | 2 Sep 2026filed 3 Sep 2026 |
| Kevin BittermanDirector | sold | 511at $80.17 | 2 Sep 2026filed 3 Sep 2026 |
| Kevin BittermanDirector | sold | 10at $80.98 | 2 Sep 2026filed 3 Sep 2026 |
| Kevin BittermanDirector | sold | 9at $80.98 | 2 Sep 2026filed 3 Sep 2026 |
Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.
Institutions
Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.
| Manager | Shares | Change |
|---|---|---|
| FMR LLCreduced · filed 13 Aug 2026 | 4,894,473$358.0M | -692,421−12.4% |
| BlackRock, Inc.added · filed 7 Aug 2026 | 2,467,899$180.5M | +194,068+8.5% |
| RA CAPITAL MANAGEMENT, L.P.unchanged · filed 14 Aug 2026 | 2,450,221$179.2M | 00.0% |
| JPMORGAN CHASE & COnew · filed 12 Aug 2026 | 1,875,795$139.9M | +1,875,795 |
| WELLINGTON MANAGEMENT GROUP LLPadded · filed 14 Aug 2026 | 1,741,351$127.4M | +5,975+0.3% |
| STATE STREET CORPreduced · filed 7 Aug 2026 | 1,648,836$120.6M | -49,408−2.9% |
| Vestal Point Capital, LPadded · filed 14 Aug 2026 | 1,550,000$113.4M | +850,000+121.4% |
| Atlas Venture Life Science Advisors, LLCunchanged · filed 13 Aug 2026 | 1,513,875$110.7M | 00.0% |
| VANGUARD CAPITAL MANAGEMENT LLCreduced · filed 13 Aug 2026 | 1,369,027$100.1M | -6,403−0.5% |
| Frazier Life Sciences Management, L.P.unchanged · filed 14 Aug 2026 | 1,354,852$99.1M | 00.0% |
News
Everyone who traded it
Same industry
Government contracts
No federal award is tied to it.
From its SEC filings
Analyst forecasts
No analyst forecasts yet.